

To: Janet M Hart[jhart@riteaid.com]
From: Kevin Nicholson
Sent: 2012-10-10T15:45:35-04:00
Importance: Normal
Subject: RE: Time Sensitive - Drafts Comments to FDA on Hydrocodone Rescheduling
Received: 2012-10-10T15:43:35-04:00

Thanks Janet!

Kevin N. Nicholson, R.Ph., J.D.
Government Affairs and Public Policy
National Association of Chain Drug Stores
Tel: 703-837-4183

From: Janet M Hart [mailto:jhart@riteaid.com]
Sent: Wednesday, October 10, 2012 3:39 PM
To: Kevin Nicholson
Subject: FW: Time Sensitive - Drafts Comments to FDA on Hydrocodone Rescheduling
Importance: High

I am fine....

From: Kevin Nicholson [mailto:KNicholson@NACDS.org]
Sent: Wednesday, October 10, 2012 1:15 PM
To: Al Carter; Albert Garcia (albert.garcia@navarro.com); Alethia Jackson (Alethia.jackson@walgreens.com); Allen Horne; Andrew Helm; Anna.Shimanek@target.com; arrowpharmacy@aol.com; Averill Gordon; barry.jasilli@caremark.com; Beth Cieslik; Bob Egeland; Bob Stone; Bogdan, Jay; Brian Files (brian.files@cvscaremark.com); Bryan Schneider; Cartier, Eric R.; cary.mergele@searshc.com; Charlie.Oltman@target.com; Cheryl Zambrowicz (cheryl.zambrowicz@shopko.com); Christine Simmon; Dadrion Gaston; Darren Townzen; David Sencabaugh; Debbie Garza; Debbie Mack; Ed.Kaleta@walgreens.com; Elliott Sogol; Eric P. Douglas (Eric.Douglas@CVSCaremark.com); Fred Ottolino; Grace R Schuyler; Gregory, Steven; Heather.Smith@Walgreens.com; Isaac Reyes; Janet M Hart; Jon McArthur; 'Jonathan Wong'; Kay Hanson; Ken Curry; Kevin Nicholson; Lisa Krause; Margaret.Nowak@walgreens.com; Mark Gregory; Mark McGrew; Mark Polli; Maxine Johnson; Michael A. Moné (michael.mone@cardinalhealth.com); Michael Mastromonica; Michele Davidson; Mike Ayotte; Mike A. Podgurski; Mike Sargent; Nicholas Cichowicz; Nick Dorich; Papatya Tankut; Read, Douglas; Rowley, Lauren M; Stephanie Kent; Tim.Koch@wal-mart.com; Tomson George; Tony Unan; Victor Curtis; Wendy Chew; 'Wiesner,Dennis'
Cc: Govt Affairs and Public Policy
Subject: Time Sensitive - Drafts Comments to FDA on Hydrocodone Rescheduling
Importance: High

Attached are draft comments to FDA, advocating that FDA should not recommend rescheduling combination hydrocodone products into Schedule II.

Comments are due to FDA on Monday, October 15. Please send me your feedback **before October 15.**

As a reminder, NACDS will also testify at the FDA public hearing on this matter on October 30.



Kevin N. Nicholson, R.Ph., J.D.
Government Affairs and Public Policy
National Association of Chain Drug Stores
Tel: 703-837-4183
knicholson@nacds.org
www.nacds.org

Twitter – @NACDS
Facebook – facebook.com/NACDS.org